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Abstract
Background/Objectives: Breast milk contains lutein derived from the mother's diet. This carotenoid is currently not 
added to infant formula, which has a small and variable lutein content from innate ingredients. This study was 
conducted to compare the growth of infants fed lutein-fortified infant formula with that of infants fed infant formula 
without lutein fortification.
Subjects/Methods: This 16-week study was prospective, randomized, controlled, and double-blind with parallel 
groups of healthy term infants fed either control formula (Wyeth S-26 Gold, designated as Gold) or experimental 
formula (Wyeth S-26 Gold fortified with lutein at 200 mcg/l, designated as Gold + Lutein). Two hundred thirty-two 
(232) infants ≤ 14 days postnatal age were randomized and 220 (94.8%) completed the study. Weight (g), head 
circumference (cm), and length (cm) were measured at Weeks 4, 8, 12, and 16. The primary endpoint was weight gain 
(g/day) from baseline to Week 16. Safety was assessed through monitoring of study events (SEs) throughout the study 
and evaluation of selected blood chemistry tests performed at Week 16.
Results: Infants in both treatment groups demonstrated appropriate growth. No differences between treatment 
groups were found in any of the measures of growth at any of the measurement time points. Both study formulas were 
well tolerated. The mean values of all measured blood chemistry parameters fell within the modified normal ranges for 
infants, and the values for both groups for any measured parameter were similar.
Conclusions: Infants fed lutein-fortified S-26 Gold demonstrated growth equivalent to that of infants fed unfortified 
lutein formula.
Introduction
Lutein and zeaxanthin are xanthophylls in the family of
carotenoids found in common foods including spinach,
peas, and broccoli. These compounds are unique being
highly concentrated in the macular region of the retina
and function as antioxidants and as filters for high-energy
blue light [1]. Studies in primates and in adults suggest
that lutein and zeaxanthin may help provide protection
against oxidative and "blue light" damage [2,3]. Lutein is a
structural component of the eye and is a potent antioxi-
dant. Lutein is well suited for protecting the retina from
oxidative damage compared with other chain-breaking
antioxidants in the eye like alpha-tocopherol (Vitamin E).
Lutein can return singlet oxygen to ground state by tem-
porarily becoming triplet-state lutein and then dissipat-
ing the energy as heat. This process can be repeated over
and over again, because the lutein molecule remains
intact after the energy transfer [4]. No data currently
exists which demonstrates that lutein supplementation
can influence visual acuity in infants, though some stud-
i e s  i n  a d u l ts  wi t h  vis ua l  d i so r d e r s  h a v e  s h o wn  m od e s t
benefits [5,6].
Humans cannot synthesize these carotenoids, therefore
blood and tissue levels depend on dietary consumption.
Breast milk being the reference standard for infant for-
mula composition, contains lutein and zeaxanthin from
the mother's diet, though lutein appears to be the pre-
dominant one of the 2 carotenoids [7,8]. The levels of
lutein vary widely in breast milk. A 9-country survey con-
ducted on breast milk carotenoid composition among
471 women served as a guide to determining appropriate
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lutein supplementation levels [7]. The overall mean ± SD
from this survey for breast milk lutein plus zeaxanthin
was 25 ± 19 mcg/l, but individual country means varied
from a low of 15 ± 5 mcg/l in the U.S. to a high of 44 ± 18
mcg/l in Japan. The highest individual lutein concentra-
tion measured was 232 mcg/l in China and the lowest was
3 mcg/l in the U.K. These carotenoids are currently not
added to infant formula, which has a small and variable
innate amount of lutein.
The primary objective of this clinical trial was to com-
pare the growth of healthy term infants fed either Wyeth
S-26 Gold (designated as Gold), an infant formula cur-
rently marketed by Wyeth Nutrition, or Wyeth S-26 Gold
fortified with lutein at 200 mcg/l (designated as Gold +
Lutein) for 16 weeks.
The lutein used in fortification of the formula was
derived from the marigold flower (Tagetes erecta L). The
raw material used was Lutein 20% liquid in Safflower Oil
sourced from Kemin Health L.C. (Des Moines, Iowa,
USA). This source of lutein also contains zeaxanthin in a
ratio of 13:1, lutein:zeaxanthin, and has been determined
by the WHO/FAO/Codex Joint Evaluation Committee on
Food Additives (JECFA) to be safe for use as a nutrient
fortification with an Allowable Daily Intake (ADI) of 0-2
mg/kg [9].
The lutein-fortification level of 200 mcg/l corresponds
to the high end of the range of observed breast milk val-
ues and potentially could maximize functional effects to
infants without any safety risk.
Materials/Subjects and methods
The study was prospective, randomized, controlled, dou-
ble-blind with parallel groups of healthy term infants.
The trial was conducted between 07-Nov-2005 and 03-
May-2006 at 2 study centers: Asian Hospital Medical
Center in Muntinlupa City and Pula Health Center in
Cabuyao Laguna, Philippines. The Institutional Review
Boards/Institutional Ethics Committees (IRB/IEC) of the
participating centers approved the study protocol. Infants
were randomized into one of two formula groups: Gold
or Gold + Lutein, if they met the study's inclusion/exclu-
sion criteria and their parent(s)/legal guardian(s) had
made a decision to formula feed their infant prior to
study screening and had signed the IRB/IEC-approved
informed consent.
Anthropometry data collection procedures were
adapted from the Department of Health and Human Ser-
vices 2000a. This involved the use of two study-associ-
ated examiners for each infant.
Study population
Two hundred forty (240) healthy full term Asian infants ≤
14 days of age were screened and enrolled. Of these
enrolled infants, 232 were randomized to one of the 2 for-
mula groups. One hundred sixteen (116) infants were
randomized to each formula group with 110 infants in
each group completing the study. Of the 116 infants ran-
domized to each formula group, one infant in each group
never received formula at the request of the parent(s)/
legal guardian(s) (see Table 1). Infants could be removed
from the study at any time at the request of the parent(s)/
legal guardian(s), sponsor, or investigator due to formula
intolerance, administration of prohibited medications/
therapies, and noncompliance with the study protocol.
Prior to enrollment into the study infants were fed in
accordance with maternal choice and hospital practices.
There were no infants who consumed a prohibited ther-
apy or non-study feed during the study.
Study feedings
The study formulas [Gold (control formula) and Gold +
Lutein (experimental formula)] were supplied as ready-
to-feed liquid, in 250-mL tetrabriks. The 4-month for-
mula supply for each infant was labeled with a unique
package number to mask the identity of the formulas.
Each study infant was assigned one package number
upon randomization and enrollment to the study. The 2
study formulas had the same composition of micronutri-
ents and macronutrients with the exception of lutein,
which was added at 200 mcg/l to Gold + Lutein.
Study formula was fed ad libitum. Study formula intake
was assessed by parents/legal guardians using a formula
weighing scale and recording study formula intake during
a 3-day period at Weeks 4, 8, and 12.
The Per-Protocol (PP) population consisted of those
infants who did not violate the protocol and who com-
pleted the study. Infants consuming any amount of study
formula were to be included in the Intention-to-Treat
(ITT) analysis. Non-study feeds were defined as any feed-
ing other than assigned study formula that contributed
more than 315 KJ (75 Kcal)/day to the infant's diet.
Randomization
A computer-generated-randomization schedule was used
to assign study formula, and the schedule was stratified
by gender and assignments balanced per block of four.
Infants were randomized (1:1) to receive one of the 2
feeding regimens.
Efficacy and safety parameters
Infants were evaluated at baseline (designated as Week 0,
which could encompass the time period from birth
through Day 14 of life) and Weeks 4, 8, 12, and 16.
The primary efficacy outcome measure was infant
growth as assessed by weight gain, expressed in grams
per day, from baseline to Week 16. Other measures of
growth including gains in length and head circumference
were assessed. Anthropometry data collection was car-
ried out according to protocol-specified methods. WeightCapeding et al. Nutrition Journal 2010, 9:22
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was determined to the nearest 0.01 kg. Length was mea-
sured using a length board with a fixed headpiece and a
moveable foot piece. Head circumference was measured
using a non-stretchable flexible measuring tape. Growth
of the infants was compared against US Center for Dis-
ease Control (CDC) reference data found on http://
www.cdc.gov/growthcharts/[10] as well as Philippine ref-
erence growth curves [11] for head circumference. These
analyses provided z-scores and percentiles for weight-for-
age, length-for-age, head-circumference-for-age and
weight-for-length. Secondary efficacy parameters evalu-
ated in the study were visual acuity, measured with Teller
Acuity cards, and infant temperament. Study findings
with respect to these secondary parameters are not pre-
sented here, but will be presented in future publications.
Safety of the infants was monitored by documentation
of all study events (SEs) that occurred during the study
and by analysis of a single blood sample drawn from each
infant at Week 16 and analyzed for albumin, alkaline
phosphatase, total bilirubin, blood urea nitrogen (BUN),
calcium, creatinine, glucose, phosphorus, and total pro-
tein. A single blood sample was chosen to minimize the
number of venipunctures for each infant and only serum
chemistries were assessed to minimize the amount of
blood withdrawn from each infant. Comparisons were
made between treatment groups and also with the nor-
mal ranges for each of these parameters as proposed by
Soldin et al. [12] for a pediatric population. The values
from Soldin et al. were used, thus slightly modifying the
ranges proposed by Quintiles, the study central labora-
tory, because this modified range was considered more
r e p r e s e n t a t i v e  o f  a n  i n f a n t  p o p u l a t i o n .  T h i s  m o d i f i e d
range was reviewed and approved by the principal inves-
tigator (PI). SEs were tabulated by preferred term, body
system (system organ class), relationship to feeding for-
mula as assessed exclusively by the PI, and outcome of the
SE. Criteria for causality assessments of SEs as well as the
definition of SEs were detailed in the protocol. Each
infant received a complete medical examination at base-
line and at Week 16, including a routine fundoscopic
examination.
The PI was responsible for complying with the protocol
and adherence to GCP/ICH guidelines. A Wyeth study
monitor visited the investigator prior to the start of the
study and at regular intervals thereafter. All information
was recorded on source documents and data were
Table 1: Summary of Infant Demography, Baseline Characteristics, and Disposition
Gold Gold + Lutein Total
(n = 115) (n = 115) (n = 230)
Age (days)
n 115 115 230
mean ± SD 9.5 ± 3.42 10.0 ± 3.49 9.8 ± 3.46
min - max 1 - 14 2 - 14 1 - 14
Gender
Female (%)/Male (%) 60(52)/55(48) 58(50)/57(50) 118(51)/112(49)
Weight Mean ± SD 3169.1 ± 306 3216.6 ± 355 3193 ± 331
Study Disposition (%) 1
Infants Screened 240
Infants randomized2 116 116 232
Completed the Study 110 (95) 110 (95) 220 (95)
Discontinued the Study 6 (5) 6 (5) 12 (5)
Reason for study discontinuation (%)
Adverse Event 4 (3) 3 (3) 7 (3)
Parent/Legal Guardian Request 2 (2) 3 (3) 5 (2)
Population: Intention to Treat
n = Number of randomized subjects who received study formula.
1 The denominator used to calculate percent for study demographics is the number of subjects who received study formula.
1 The denominator used to calculate percent for study disposition entries is the number of subjects randomized.
2 Two subjects were randomized (one in each formula group) but did not receive study formula.Capeding et al. Nutrition Journal 2010, 9:22
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recorded in the case report form screens. Computerized
and manual edit checks were performed on all entered
data to ensure the data were logical and consistent.
Statistical analysis
The sample size was determined to have sufficiently large
power to exhibit that growth of the Gold group is equiva-
lent to the Gold + Lutein group as measured by average
weight gain per day (g/day) measured at W eek 16. The
two formula-fed groups are equivalent if the true differ-
ence between the means is less than 3 g/day.
To determine equivalent growth (weight gain in g/day)
between the Gold and Gold + Lutein group, a one-sided
(alpha = 0.05) test for equivalence has a 90% power to
detect a 3 g/day difference in weight with 42 infants in
each treatment/gender group, given a standard deviation
of 5.3 as estimated in a previous study [13]. Based on pre-
viously conducted trials, it was assumed that many
infants might drop out; therefore, a total sample size of
232 infants was randomized to ensure that the minimum
number of evaluable infants was at least 186.
The primary endpoint, weight gain (g/day) at Week 16,
was analyzed by using an analysis of covariance
(ANCOVA). The model includes terms for treatment,
gender, baseline age (in days), age at the Week 16 mea-
surement, and baseline weight-for-length z-scores.
A pairwise comparison between the Gold group and
the Gold + Lutein group was conducted by examining the
difference in least squares means and the associated 90%
confidence interval (CI). If the 90% CI of the difference in
least squares means was within a difference of -3 to 3 g/
day, then the two treatments were determined to be
equivalent.
The number of infants with a valid Week 16 weight
measurement is the same for the Intention-to-Treat
(ITT) population and the Per-Protocol (PP) population;
therefore, the results of the primary analysis are the same
for the two analysis populations.
Descriptive statistics (n, mean, standard deviation,
minimum, median, maximum and 90% CI) were provided
for weight, length, head circumference, weight-for-age z-
scores, weight-for-length z-scores, length-for-age z-
scores, and head circumference-for-age z-scores for each
visit for each formula-fed and gender group. Z-scores
were calculated using the SAS program offered by the
CDC found on: http://www.cdc.gov/nccdphp/dnpa/
growthcharts/resources/sas.htm[14].
Results
Demographics, baseline characteristics, and disposition
of study infants are found in Table 1. The study groups
were well matched with respect to gender (Table 1) and
with respect to maternal age, parity, birth order of the
infant (Table 2), and maternal health and socio-economic
characteristics (data not shown).
Formula intake was comparable among the two groups.
A Week 4, mean intake was virtually identical at approxi-
mately 964 mL/day and at Week 12 the Gold group had a
mean intake of 1273 mL/day and the Gold + Lutein group
consumed 1237 mL/day.
Infant weight gain was used as the primary measure of
growth. Using measurements made at baseline and
Weeks 4, 8, 12, and 16, the estimated treatment difference
of 0.781 g/day in least squares means (90% CI: -0.91, 2.47)
was within the interval of (-3 to 3) g/day and the study
formulas were considered to support equivalent growth
as shown in Table 3.
Average daily weight gain between the 2 study groups
was assessed at defined time points. As shown in Figure
1, rates of weight gain in the Gold group and the Gold +
L u t e i n  gr o u p  w e r e  s i m i la r  a t  ea c h  as s es s ed  t i m e  po i n t
during the study (Weeks 4, 8, 12, and 16); although, over
the course of the 16-week study, there was a predictable
slowing in the rate of increase in weight gain. When rates
of weight gain were analyzed by gender, the addition of
lutein to formula had no effect on weight gain at any of
the intervals at which it was measured in either the
females or the males (data not shown). The standard
deviation of weight gain (g/day) at week16 in the Gold
group, Gold + Lutein group, and overall was 5.371, 5.030
and 5.199, respectively.
Table 2: Summary of Maternal Demography and Baseline 
Characteristics
Gold Gold + Lutein Total
(n = 115) (n = 115) (n = 230)
Maternal age 
(years)
n 115 115 230
mean 27.3 28.0 27.6
std 5.96 5.54 5.76
median 26.0 27.0 27.0
m i n 1 81 81 8
m a x 4 54 04 5
Parity
1 53(46) 48(42) 101(44)
2 27(24) 28(24) 55(24)
3 23(20) 16(14) 39(17)
> = 4 12(10) 23(20) 35(15)
Population: Intention to TreatCapeding et al. Nutrition Journal 2010, 9:22
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Increased length was observed at all measurement time
points with a 24% increase in the mean length for the
Gold group and the Gold + Lutein group through Week
16. The change in the rate of increase in length was the
same in both groups at Weeks 4, 8, 12, and 16 shown in
Figure 1; although, over the course of the 16-week study,
there was a predictable slowing in the rate of increase in
length. Data were also analyzed for each gender group.
The mean rate of increase in length was no different at
any measurement time point between formula groups for
either females or males.
Both formula groups showed steady increases in mean
head circumference over the course of the study (16% in
both groups) as shown in Figure 1. Similar to the slowing
in growth rates observed with weight and length during
the study, rates of increase in head circumference also
slowed over the 16 weeks of the study. The rate of
increase in head circumference was no different between
study groups at any of the 4 measurement time points.
When the data were analyzed by gender, similar changes
in total mean head circumference increase and rate of
gain in head circumference for the Gold group and the
Gold + Lutein group were observed in both males and
females.
Filipino infant data were compared with the US CDC
growth data and z-scores for weight-for-age, weight-for-
length, length-for-age, and head circumference-for-age
were calculated using the SAS program offered by the US
CDC and found on its website:
http://www.cdc.gov/nccdphp/dnpa/growthcharts/
resources/sas.htm[10].
Comparisons using the US CDC reference data are
illustrated in Figure 2. Both formula groups had z-scores
that paralleled each other for all growth parameters; how-
ever a post-study analysis was conducted examining head
circumference data from this study compared to a Philip-
pine infant reference population [4]. These Filipino
growth charts were based on data from 26,961 Filipino
children. When compared with the Filipino growth chart,
the head circumference data of this study population fol-
lowed the growth curve that was established at the time
of the baseline measurement, demonstrating age-appro-
priate growth for this parameter. The head circumfer-
ences for the infants track a normal growth rate and are
below the 50th percentile which may be the result of a
consistent measuring technique with the placement of
the tape over this region. This is demonstrated in Figure 3
and Figure 4 for males and females, respectively.
The safety of lutein fortification was also assessed by a
comparison of blood chemistries including albumin,
alkaline phosphatase, total bilirubin, BUN, calcium, crea-
tinine, glucose, phosphorus, and total protein as well as
by a comparison between the two formula groups of fre-
quency and type of clinical SEs that were documented
during the study.
Blood samples were obtained from 220 infants, 110
infants from each treatment group. There were no clini-
cally relevant differences in the mean values between the
2 treatment groups for any of the measured parameters.
The mean values for each of the parameters were nearly
identical between groups and all mean values fell within
the range for the modified normal values. Additionally,
the fundoscopic exams were normal for both groups.
The mean laboratory values as well as the minimum
and maximum laboratory values for each parameter are
presented in Table 4. There was comparability in the lab-
oratory values between the two groups and the few values
Table 3: Summary and Formula Comparisons of Weight 
Gain (g/day) at Week 16
Gold Gold + Lutein Total
(n = 110) (n = 110) (n = 220)
Summary Statistics
n 110 110 220
mean 28.48 29.04 28.76
std 5.371 5.030 5.199
median 27.78 28.30 28.17
min 16.9 19.6 16.9
max 49.9 47.3 49.9
Model Estimate*
n 110 110 -
LS Mean 28.41 29.19 -
Standard Error 0.455 0.455 -
90% Confidence 
Interval
(27.23, 29.59) (28.01, 30.37) -
The Estimated 
Treatment 
Difference*
Gold + Lutein VS. 0.781 - -
90% Confidence 
Interval for the 
Estimated Treatment 
Difference*
Gold + Lutein VS. (-0.91, 2.47) - -
Population: Per Protocol = ITT for this parameter
* Estimates created from an analysis of covariance (ANCOVA) with 
fixed effects treatment, gender, age (in days), age at the Week 16 
measurement (in days) and baseline weight-for-length z-score.
The numbers of subjects with valid measurements in the PP (Per-
Protocol) and the ITT (Intention-to-Treat) populations are the 
same.Capeding et al. Nutrition Journal 2010, 9:22
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that were outside the normal ranges were not considered
to be clinically significant.
Among the 230 infants who consumed any amount of
formula, a total of 103 clinical SEs were reported (54
infants in the Gold group and 49 infants in the Gold +
Lutein group). There was no clinically relevant difference
in the incidence of clinical SEs between the 2 formula
groups.
All clinical SEs completely resolved during the study
period and, with the exception of the 2 events discussed
in the paragraph that follows, were considered mild to
moderate by the examining physician.
Two (2) serious SEs were reported for the Gold +
Lutein group during the study period, while none were
reported in the Gold group. Of the 2 serious SEs, one
infant was diagnosed with acute gastroenteritis and the
other was diagnosed with bronchopneumonia. Both
events were considered by the PI to be unrelated to for-
mula administration. In each case, the infant was hospi-
talized and the serious SE resolved completely.
Discussion
The objectives of this study were to assess the effects on
growth and safety of healthy term infants fed an infant
formula supplemented with lutein. No differences in any
of the growth parameters were found between formula
groups during the 16-week feeding period.
Data from our study were compared with growth data
from a large US infant population. The results of these
comparisons were calculated in the form of z-scores and
percentiles. For 3 of these 4 parameters (weight-for-age,
length-for-age and weight-for-length), the z-scores of the
study group means at baseline were less than zero, sug-
gesting the study population was smaller at the outset of
the study than a similar population of US infants of the
same age. Over the course of the study, the z-score means
for weight and length increased to values that were within
the second quartile of the US CDC data. These results
show that the infants had grown appropriately on both
study formulas and achieved growth that was comparable
to the mean of the US reference population. The mean
head-circumference-for-age data in both study groups
Figure 1 Mean Velocity Over Time by Each Treatment - Weight (g/day), Length (cm/day), and Head Circumference (cm/day) Population: 
Intention to Treat.Capeding et al. Nutrition Journal 2010, 9:22
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Figure 2 Mean Z-Scores Over Time by Each Treatment - Weight-for-Age, Weight-for-Length, Length-for-Age, and Head Circumference-for-
Age, Population: Intention to Treat.  Z-scores calculated using the SAS program offered by the US CDC and found on its website: http://
www.cdc.gov/nccdphp/dnpa/growthcharts/resources/sas.htm.
Figure 3 Head Circumference Male. Percentile curves generated 
based on data from the Nutrition Research Institute - Philippine Pedi-
atric Society (FNRI - PPS) Anthropometric Tables and Charts for Filipino 
Children (see Fiorentino et al., 1992).
Figure 4 Head Circumference Female. * Percentile curves generat-
ed based on data from the Nutrition Research Institute - Philippine Pe-
diatric Society (FNRI - PPS) Anthropometric Tables and Charts for 
Filipino Children (see Fiorentino et al., 1992).Capeding et al. Nutrition Journal 2010, 9:22
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were in the same quartile at baseline and at the end of the
study.
The frequency and severity of the SEs recorded in the
study were similar between treatment groups, were not
judged by the PI to be formula related, and in every case
the symptoms resolved. The comparability in number of
SEs between study formulas supports the conclusion that
fortification of an infant formula with lutein is safe for
infant consumption. Further support of this conclusion is
derived from the blood chemistry data that showed the
mean values of all parameters measured fell within the
modified normal ranges for infants and that the values
between groups for any parameter were no different.
From the data in this study, lutein fortification of S-26
Gold at 200 mcg/L is safe and allows normal infant
growth.
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Table 4: Incidence of Laboratory Normative Values
Test Gold Gold + Lutein
(n = 115) (n = 115)
ALBUMIN
Normal range = 2.1-4.9 g/dL
Mean ± SD
Min-Max
4.46 ± 0.25
3.8 - 5.2
4.39 ± 0.22
3.9 - 5.2
ALK PHOSPHATASE
Normal range = 60-425 U/L
Mean ± SD
Min-Max
293 ± 61.8
145 - 474
298 ± 70.4
149 - 640
BILIRUBIN TOTAL
Normal range = 0-1.0 mg/dL
Mean ± SD
Min-Max
0.24 ± 0.07
0.1 - 0.5
0.25 ± 0.08
0.1 - 0.6
BLOOD UREA NITROGEN (BUN)
Normal range = 1-14 mg/dL
Mean ± SD
Min-Max
6.52 ± 1.6
4 - 14
6.39 ± 1.52
3 - 11
CALCIUM (mg/dl)
Normal range = 7.7-11.5 mg/dL
Mean ± SD
Min-Max
10.64 ± 0.37
9.8 - 11.9
10.58 ± 0.34
9.7 - 11.6
CREATININE (mg/dl)
Normal range = 0.2-0.4 mg/dL
Mean ± SD
Min-Max
0.29 ± 0.028
0.2 - 0.3
0.29 ± 0.039
0.1 - 0.4
GLUCOSE (mg/dl)
Normal range = 57-117 mg/dL
Mean ± SD
Min-Max
83.6 ± 8.8
56 - 105
82.9 ± 9.8
45 - 111
PHOSPHORUS (mg/dl)
Normal range = 3.0-7.5 mg/dL
Mean ± SD
Min-Max
6.5 ± 0.46
5 - 7.6
6.43 ± 0.53
4.8 - 9.8
PROTEIN TOTAL (g/dl)
Normal range = 3.9-7.9 g/dL
Mean ± SD
Min-Max
6.58 ± 0.42
5.7 - 7.7
6.43 ± 0.33
5.6 - 7.2
Population: Intention to Treat
Ranges are from Soldin SJ et al. (1999).Capeding et al. Nutrition Journal 2010, 9:22
http://www.nutritionj.com/content/9/1/22
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